Tolerability of tiagabine: a prospective open-label study.
Tiagabine was used as add-on therapy in the treatment of epilepsy with partial and/or secondarily generalised seizures to evaluate tolerability and efficacy. Five hundred and seventy-four patients (299 men and 275 women, mean age 38.1 years), with refractory partial seizures, were enrolled in this prospective, open-label study. Tiagabine was added to one (44.1%) or more (up to nine) antiepileptic drugs. The median daily dose of tiagabine was 30 mg (mean 29.1, SD 12.0). The mean duration of follow-up was 94.9   42.7 days. 12.3% of patients were completely seizure-free at the end of the observation period. Median total seizure frequency decreased from 4.5 to 2.0 seizures/4 weeks. Adverse events occurred in 78 patients (13.6%). Tiagabine proved to be a well-tolerated AED.
Bauer
Jürgen
J
Department of Epileptology, University of Bonn, Germany. juergen.bauer@ukb.uni-bonn.de
Bergmann
Arnfin
A
Reuber
Markus
M
Stodieck
Stefan Rudolf Günther
SR
Genton
Pierre
P
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D003072:Cognition Disorders / Q000139:chemically induced / Q000523:psychology; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000145:classification / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced / Q000523:psychology; D008875:Middle Aged; D009557:Nipecotic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D011446:Prospective Studies; D013226:Status Epilepticus / Q000209:etiology; D000078308:Tiagabine
D000927:Anticonvulsants; D009557:Nipecotic Acids; D000078308:Tiagabine